Dan Janney
Managing Director @ Alta Partners
San Francisco, United States
Dan Janney is a Series A investor at Alta Partners in San Francisco focused on Biotechnology and Therapeutics. Dan Janney is based out of San Francisco, California and is the Managing Director of Alta Partners. Dan previously worked at Georgetown University as a board of regents. Dan Janney attended the Georgetown University.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Dan Janney invests in
Stages Dan Janney invests in
Countries Dan Janney invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 8 (57%)
- Therapeutics 4 (29%)
- Medical 3 (21%)
- Health Care 3 (21%)
- Life Science 3 (21%)
Stage
- Series A 6 (43%)
- Series B 3 (21%)
- Funding Round 2 (14%)
- Series C 1 (7%)
- Debt Financing 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms. | $65M / Series A / May 14, 2024 | ||
| Edgewood Oncology is a clinical-stage biotechnology business established to fulfill the potential of BTX-A51 for patients with solid tumors that are genetically specified and hematologic malignancies. Our goal is to create a novel treatment that will prolong and enhance the lives of those with the greatest unmet medical needs. | $20M / Series A / Mar 25, 2024 | ||
| Lassen Therapeutics develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. The company’s lead candidate is LASN01, a monoclonal antibody targeting IL-11 receptor alpha (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis, and blocking its activity has the potential to be moreeffective than targeting other factors such as TGF-β and CTGF. IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells. | $85M / Series B / Dec 19, 2023 | ||
| Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications. | $43.5M / Series B / Sep 13, 2022 | ||
| DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints. | $70M / Series A / Jun 23, 2022 | ||
| ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases. | $50M / Series A / Jun 23, 2021 | ||
| Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications. | $33M / Series A / Jan 07, 2020 | ||
Virobay
|
Virobay, Inc. operates as an anti-viral drug discovery and development company. It engages in developing, investigating, and creating treatments for hepatitis C, such as protease and polymerase inhibitors. The company was founded in 2006 and is headquartered in Menlo Park, California. | $8M / Series B / Jul 16, 2014 | |
| Lithera is developing products for aesthetic medicine to address both medical and lifestyle indications. Its lead product is an injectable treatment to achieve local, selective fat tissue reduction (pharmaceutical lipoplasty). Using FDA registered drugs proven safe and effective in other indications, its product targets and stimulates natural fatmetabolism and achieves non-ablative, non-surgical fat tissue reduction in specific locations. | $8M / Series C / Feb 12, 2014 | ||
| Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Its prescription medicines focus on lowering elevated low-density lipoprotein cholesterol (LDL-C), a key factor in cardiovascular disease. The company offers oral, non-statin therapies that help reduce cardiovascular risk in patientswho are unable to tolerate or adequately respond to standard statin treatments. Its marketed products include bempedoic acid-based therapies that work by inhibiting ATP citrate lyase (ACLY), an enzyme involved in cholesterol synthesis. These medicines are designed to reduce LDL-C levels and support cardiovascular risk reduction in adults with conditions such as hyperlipidemia and atherosclerotic cardiovascular disease. | $33M / Apr 25, 2013 | ||
| See all 14 investments → | |||
Co-Investors
About Alta Partners
Alta Partners is a venture capital firm investing in the healthcare and life sciences sector. Their diverse and integrated team brings together a powerful depth of knowledge and experience, delivering tangible results for their companies and their investors.
Alta Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Dan Janney
Managing Director
|
|||
Peter Hudson
Managing Director
|
|||
|
Alison de Bord
Director
|
|||
Bob More
Managing Director
|
|||
Edward Penhoet
Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dan Janney invest in?
Dan Janney invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Dan Janney?
Public channels for Dan Janney include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Dan Janney last invest?
The most recent investment recorded for Dan Janney closed in May 2024. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
